UK-based biotech Oxford BioMedica is working with Novartis in a transformational deal for the firm worth $90 million to develop …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

